This is the authors' abstract. We don't add key points for this paper.
This contribution describes part 1 of process development of a novel aldose reductase inhibitor FK366 ( 1 ). The original process applied on a laboratory scale was improved from the safety viewpoint to manufacture materials on 500-L scale suitable for toxicological and pharmacological evaluations. A new process, including regioselective alkylation of silylated quinazolinedione, provided a practical and cost-effective synthesis of FK366 in a dramatically increased yield.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Goto et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: